Select the Guidelines & Statements drop-down menu near the top of the web page, then click Publication Development. Permissions: Multiple copies, modification, alteration, enhancement, and/ or distribution of this document are not permitted without the express permis- sion of the American Heart Association. Instructions for obtaining permission are located at https://www.heart.org/permissions. A link to the Copyright Per- missions Request Form appears in the second paragraph (https://www.heart. org/en/about-us/statements-and-policies/copyright-request-form). REFERENCES 1.1. Methodology and Evidence Review S1.1-1. Wilson PWF, Polonsky TS, Miedema MD, et al. Systematic review for the NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1144 61. DOI: 10.1161/CIR.0000000000000626. 1.4. Scope of the Guideline S1.4-1. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet. 2010;376:1670 81. S1.4-2. Chou R, Dana T, Blazina I, et al. Statin use for the prevention of car- diovascular disease in adults: a systematic review for the US Preventive Services Task Force. 2016. Rockville, MD: US Agency for Healthcare Research and Quality, Report No.: 14-05206-EF-2. S1.4-3. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013:CD004816. S1.4-4. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guide- line on the treatment of blood cholesterol to reduce atheroscle- rotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1 45. 1.5. Class of Recommendation and Level of Evidence S1.5-1. Halperin JL, Levine GN, Al-Khatib SM, et al. 